Tammenoms Bakker Juliet's Form 4 filing
Vera Therapeutics, Inc. (VERA) · filed Feb 8, 2023
- Accession no.
- 0000899243-23-004349
- Filed
- Feb 8, 2023, 7:40 PM ET
- Trade date
- Feb 6, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $12.0M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tammenoms Bakker JulietCIK 0001431159 | 10% Owner |
| Longitude Venture Partners IV, L.P.CIK 0001787456 | 10% Owner |
| Longitude Capital Partners IV, LLCCIK 0001829169 | 10% Owner |
| Longitude Prime Partners, LLCCIK 0001865779 | 10% Owner |
| Longitude Prime Fund, L.P.CIK 0001865844 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 6, 2023 | Class A Common Stock | PPurchaseAcquired | +1,714,285 | $7.00 | +$11,999,995 | 1,714,285 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Mr. Enright, a managing member of LPP and LCP IV, currently serves on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer.